Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium

Core Insights - Corbus Pharmaceuticals Holdings, Inc. is participating in the Piper Sandler Virtual Oncology Symposium on October 9-10, 2025, with CEO Yuval Cohen, Ph.D. scheduled for a Fireside Chat [1][2] Company Overview - Corbus is a clinical stage oncology and obesity company focused on innovative scientific approaches to combat serious illnesses [2] - The company's pipeline includes: - CRB-701: A next-generation antibody drug conjugate targeting Nectin-4 on cancer cells [2] - CRB-601: An anti-integrin monoclonal antibody that blocks TGFβ activation on cancer cells [2] - CRB-913: A highly peripherally restricted CB1 receptor inverse agonist for obesity treatment [2] - Corbus is headquartered in Norwood, Massachusetts [2]